Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
出版年份 2017 全文链接
标题
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
作者
关键词
-
出版物
RHEUMATOLOGY
Volume 56, Issue 11, Pages 1993-2003
出版商
Oxford University Press (OUP)
发表日期
2017-07-26
DOI
10.1093/rheumatology/kex301
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study
- (2017) Arthur Kavanaugh et al. ARTHRITIS CARE & RESEARCH
- Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
- (2016) Vibeke Strand et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
- (2016) A. Kavanaugh et al. JOURNAL OF RHEUMATOLOGY
- Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
- (2016) Désirée van der Heijde et al. Arthritis & Rheumatology
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quando anti‐TNF não obtém sucesso, anti‐IL‐12‐23 é opção alternativa na psoríase e na artrite psoriásica
- (2014) Ricardo Prado Golmia et al. Revista Brasileira De Reumatologia
- Burden of Disease: Psoriasis and Psoriatic Arthritis
- (2013) Wolf-Henning Boehncke et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study
- (2013) Karen Minde Fagerli et al. ANNALS OF THE RHEUMATIC DISEASES
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study
- (2013) V. Strand et al. JOURNAL OF RHEUMATOLOGY
- Recomendações sobre diagnóstico e tratamento da artrite psoriásica
- (2013) Sueli Carneiro et al. Revista Brasileira De Reumatologia
- A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis
- (2011) Zoe Ash et al. ANNALS OF THE RHEUMATIC DISEASES
- Work disability and health-related quality of life in males and females with psoriatic arthritis
- (2008) M Wallenius et al. ANNALS OF THE RHEUMATIC DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search